HROW · XBRL financial data

Harrow financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HROW's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	48,871	72,476	88,595	130,193	199,614	272,303
Cost of goods and services sold	14,463	18,214	25,383	39,640	49,245	67,934
Gross profit	34,408	54,262	63,212	90,553	150,369	204,369
Research and development	2,413	11,084	3,050	6,652	12,230	20,940
Selling, general and administrative	31,247	41,315	58,243	83,090	129,064	152,914
Total operating expenses	34,023	52,648	61,293	90,122	141,547	173,854
Operating income (loss)	385	1,614	1,919	431	8,822	30,515
Interest expense	—	5,436	7,244	21,324	22,786	24,180
Other income (expense)	(73)	197	102	(444)	(185)	47
Income tax expense (benefit)	4	133	75	701	161	3,771
Net income (loss)	(3,357)	(18,007)	(14,086)	(24,411)	(17,481)	(5,139)
Earnings per share, basic USD per share	(0.13)	(0.69)	(0.51)	(0.75)	(0.49)	(0.14)
Earnings per share, diluted USD per share	(0.13)	—	(0.51)	(0.75)	(0.49)	(0.14)
Weighted average shares, basic thousands of shares	25,895	26,757	27,461	32,617	35,651	36,760
Weighted average shares, diluted thousands of shares	25,895	—	27,461	32,617	35,651	36,760

Fiscal years (HROW's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	4,101	42,167	96,270	74,085	47,247	72,927
Short-term investments	28,455	8,503	5,589	8,681	—	—
Accounts receivable	2,662	4,470	6,249	36,261	116,373	110,895
Inventory	3,962	4,217	6,541	10,867	10,702	13,523
Prepaid and other current assets	751	1,305	3,611	9,588	15,329	14,405
Total current assets	40,131	60,662	118,260	139,482	189,651	211,750
Property and equipment, net	4,453	3,141	3,486	3,521	3,734	3,260
Right-of-use asset	6,799	5,935	7,513	6,785	8,554	7,783
Goodwill	332	332	332	332	332	332
Total assets	57,474	98,329	157,378	312,164	388,971	399,482
Accounts payable	—	—	—	—	38,762	35,355
Total current liabilities	10,799	9,722	18,632	49,344	91,343	96,302
Lease liability, non-current	6,652	6,012	7,332	6,524	8,792	7,905
Total liabilities	30,646	87,398	130,138	241,753	319,674	347,391
Accumulated deficit	(77,400)	(95,407)	(109,493)	(133,904)	(151,385)	(156,524)
Total stockholders' equity	27,183	11,286	27,595	70,766	69,652	52,446
Total liabilities and equity	57,474	98,329	157,378	312,164	388,971	399,482
Common shares outstanding (cover page) thousands of shares	25,983	27,030	29,968	35,363	35,654	37,230

Fiscal years (HROW's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(3,357)	(18,007)	(14,086)	(24,411)	(17,481)	(5,139)
Stock-based compensation	2,775	5,745	7,974	15,696	17,619	12,502
Net cash from operating activities	(1,100)	5,082	1,705	3,840	(22,202)	43,864
Purchases of property and equipment	862	1,786	2,597	1,460	1,595	887
Net cash from investing activities	(981)	(18,686)	(1,743)	(152,553)	(33,164)	(5,460)
Proceeds from issuing common stock	—	—	22,655	64,520	—	—
Net cash from financing activities	1,433	51,470	54,141	126,528	28,528	(12,724)
Net change in cash	(648)	37,866	54,103	(22,185)	(26,838)	25,680

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Harrow	83,889	70,661	(9,755)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	45,792	83,699	46,367*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Novavax	191,458	56,698	(72,807)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026
Neogen	172,000	222,800	12,900	218.3M	—	Q1 FY27 10-QAug 31, 2026
Akebia Therapeutics	155,548	49,128	3,525*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Viridian Therapeutics	172,860	25,752	not reported	113.6M	—	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	129,467	199,878	71,323*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46,317	127,655	2,171*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Spyre Therapeutics	82,727	not reported	(77,495)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.